Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Loupakis

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|March 26, 2008
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsG Allegrini, A Falcone, A Fioravanti, et al.
British Journal of Cancer|March 17, 2011
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerF Loupakis, C Cremolini, A Fioravanti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patientsF Crea, L Fornaro, E Paolicchi, et al.
The Pharmacogenomics Journal|December 24, 2014
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapyM K H Maus, D L Hanna, C L Stephens, et al.
British Journal of Cancer|May 14, 2009
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancerE Vasile, G Masi, L Fornaro, et al.
The Pharmacogenomics Journal|December 10, 2014
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancerP Bohanes, D Yang, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2010
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practiceD Santini, C Spoto, F Loupakis, et al.
The Pharmacogenomics Journal|July 30, 2014
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancerN B Volz, S Stintzing, W Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
The Pharmacogenomics Journal|February 24, 2010
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanF Graziano, E Canestrari, F Loupakis, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|March 26, 2008
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsG Allegrini, A Falcone, A Fioravanti, et al.
British Journal of Cancer|March 17, 2011
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerF Loupakis, C Cremolini, A Fioravanti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patientsF Crea, L Fornaro, E Paolicchi, et al.
The Pharmacogenomics Journal|December 24, 2014
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapyM K H Maus, D L Hanna, C L Stephens, et al.
British Journal of Cancer|May 14, 2009
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancerE Vasile, G Masi, L Fornaro, et al.
The Pharmacogenomics Journal|December 10, 2014
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancerP Bohanes, D Yang, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2010
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practiceD Santini, C Spoto, F Loupakis, et al.
The Pharmacogenomics Journal|July 30, 2014
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancerN B Volz, S Stintzing, W Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
The Pharmacogenomics Journal|February 24, 2010
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanF Graziano, E Canestrari, F Loupakis, et al.
Pageof 6